Eli Lilly said it expects significant production increases in the second half of the year for its obesity treatment and related diabetes drug Mounjaro
weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2-billion on Tuesday, lifting its shares nearly 6 per cent.
The company said sales growth will depend on how much of the medicines it can produce and ship in the short to mid-term. Indianapolis-based Eli Lilly and Danish rival Novo Nordisk are racing to increase production in a weight-loss market estimated to reach at least $100-billion by decade’s end. Both companies’ obesity treatments belong to a class of drugs originally developed for diabetes known as GLP-1 agonists.
The U.S. Food and Drug Administration has said most doses of Zepbound and Mounjaro are expected to be in shortage through the second quarter of this year. Mounjaro sales, however, came in below Wall Street estimates of $2.08-billion, which analysts attributed to limited supply. That amounts to a total of more than 1 million Zepbound prescriptions, and around 1.75 million for Wegovy, written in the United States since the start of 2024.
Canada News Breaking News Video Canadian Breaking News Breaking News Globe And Mail Breaking News Globe And Mail Canada News Photos World News Local News National News Us News Foreign News Sports News Arts News Life News Lifestyle Canada Traffic Canada Weather Trudeau Government Federal Government Canada Sports Canada Sports News Politics Politics News Political News Political Opinion Environment Economy Technology Education Travel Canada Alberta Bc British Columbia Manitoba Ontario Quebec Nova Scotia Pei New Brunswick Newfoundland And Labrador Nunavut Northwest Territories Yukon Globe And Mail
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Top 2024 NHL Draft prospect Macklin Celebrini wins 2024 Hobey Baker AwardCelebrini beat out Boston College’s Cutter Gauthier (Anaheim Ducks) and North Dakota’s Jackson Blake (Carolina Hurricanes) to become the youngest...
Read more »
Lilly Raises 2024 Guidance as Zepbound Keeps Flying Off ShelvesEli Lilly & Co. raised its annual outlook for sales and profit as the company labored to satisfy soaring demand for its blockbuster weight-loss and diabetes drugs.
Read more »
Auto parts seller LKQ cuts 2024 sales forecast as warm weather slows demand'Our first-quarter results were below our expectations as our Wholesale – North America segment was confronted with a reduction in repairable claims and the ...
Read more »
Eaton raises 2024 profit forecast on strong industrial equipment demandExplore stories from Atlantic Canada.
Read more »
Healthpeak Properties increases 2024 FFO forecast owing to higher demandExplore stories from Atlantic Canada.
Read more »
Merck raises 2024 guidance on cancer drug demandShares of Merck & Company (MRK) are trading higher early Thursday after the pharmaceutical giant posted robust sales results in the first quarter, leading...
Read more »